Another area of significant biotech breakthrough in 2023 is the development of new weight-loss drugs called GLP-1 analogues – which mimic the GLP-1 hormone that is released in the gut in response to eating.
Another area of significant biotech breakthrough in 2023 is the development of new weight-loss drugs called GLP-1 analogues – which mimic the GLP-1 hormone that is released in the gut in response to eating. These drugs are moving beyond traditional appetite suppressants to target underlying metabolic pathways and hormonal imbalances associated with obesity. This shift represents a more nuanced understanding of obesity’s biological underpinnings and opens up new possibilities for effective treatment options​​.